Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression

BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. The objective of this study was to compare the anti-tumor activity of HER2/neu-targeting monoclonal antibodies, trastuzumab (T), pertuzumab (P), combination of trastuzumab and pertuzumab (T+P) and trastuzumab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol
Hlavní autoři: Menderes, Gulden, Bonazzoli, Elena, Bellone, Stefania, Altwerger, Gary, Black, Jonathan D., Dugan, Katherine, Pettinella, Francesca, Masserdotti, Alice, Riccio, Francesco, Bianchi, Anna, Zammataro, Luca, deHaydu, Christopher, Buza, Natalia, Hui, Pei, Wong, Serena, Huang, Gloria S., Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5605415/
https://ncbi.nlm.nih.gov/pubmed/28705408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.07.009
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky